Development of next-generation neuromodulatory therapeutics by quadripulse transcranial magnetic stimulation for Schizophrenia and Autism Spectrum Disorder - Next-generation neuromodulatory therapeutics by QPS for schizophrenia and ASD

Kitahata Ryosuke0 个研究点目标入组 80 人开始时间: 2023年3月9日最近更新: 2023年10月17日

试验速览

暂无简介。

•1) Patients who meet the diagnostic criteria for schizophrenia/schizoaffective disorder or autism spectrum disorder in the DSM-5
•2) Patients who have provided written informed consent to participate in this study
•3) Male and female patients aged 20 to 65 at the time of obtaining written informed consent
•4) Patients who have been attending the hospital regularly and have not changed their psychotropic drug for the past 3 months

•1) Patients with cerebral organic diseases (intermediate intracranial organic lesions or neurodegenerative diseases, etc.)
•2) Patients with a history of seizures or epilepsy
•3) Patients with a history of substance use disorders in the past 6 months
•4) Patients who has received electroconvulsivetherapy in the past 6 months
•5) Patients with serious or unstable physical illness
•6) Patients being pregnant, breastfeeding, or hoping to become pregnant
•7) Patients with alcohol allergy
•8) Patients with contraindications to TMS or MRI procedures such as metal implants, pacemakers, claustrophobia, tattoos (including art makeup) larger than a single point (2 x 2 cm) on the head and neck
•9) Patients whose head, neck, or body size is not suitable for MRI scanner
•10) Patients who are judged to be inappropriate by the principal investigator or co-investigators

发起方

Kitahata Ryosuke